Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 (2022)

Peer-Reviewed Study · Chuang ST; Papp H; Kuczmog A; Eells R; Condor Capcha JM; Shehadeh LA; Jakab F; Buchwald P · May 18, 2022

Chuang ST et al., 2022-05-18: Pharmacology paper showing methylene blue blocks the SARS-CoV-2 spike-ACE2 interaction at 1-5 microM but does so promiscuously across unrelated protein-protein interactions, which limits how much the antiviral readings can be attributed to a specific mechanism.

Methylene blue also showed promiscuous activity and inhibited several other PPIs of viral proteins (e.g., HCoV-NL63-ACE2, hepatitis C virus E-CD81) as well as others (e.g., IL-2-IL-2Rα) with similar potency.

Abstract

Chuang ST et al., 2022-05-18: Pharmacology paper showing methylene blue blocks the SARS-CoV-2 spike-ACE2 interaction at 1-5 microM but does so promiscuously across unrelated protein-protein interactions, which limits how much the antiviral readings can be attributed to a specific mechanism. Study type: in vitro biochemical and cell assays (PPI inhibition, pseudovirus entry, Vero E6 replication with qPCR). Country: USA/Hungary collaboration (University of Miami, Pecs). IC50 1-5 uM for spike-ACE2; 1.7 uM for replication. Funding: NIH R01 HL140468. Conflicts: none declared. Bearing: supports that MB has measurable antiviral activity, but the authors' own framing , 'nonspecific' and 'promiscuous' , cuts against claims of a targeted antiviral mechanism. Study type: lab.